To present simple, objective, and customizable cost estimation formulas to compare per-attack treatment costs of four recently FDA-approved hereditary angioedema (HAE) products. METHODS: Products developed for small orphan disease populations such as HAE are predictably costly. Comparing treatment costs among new HAE therapies is complicated by differences in dosing recommendations and re-dosing probabilities. We propose a simple cost estimation formula that factors in the non-static variables of body weight and re-dosing likelihood per attack based on official prescribing recommendations and published clinical study data. Other administrative or indirect costs were not factored into the formulas. RESULTS: Formulas were developed that allow insertion of local acquisition costs for any of the HAE products, according to the quantity of vials or syringes required for initial dosing. A weighted percentage of the cost of the initial dose was added to determine the total cost, factoring in the anticipated need for re-dosing. For products having more than one published re-dosing frequency, the lowest reported frequency was used as a conservative approach. Specific cost estimation formulas address three theoretical patient weight categories: < 40 kg (to reflect small adults or pediatric patients), a standard 75 kg adult, and obese patients weighing between 100-125 kg. CONCLUSIONS: While therapy choices in HAE should be primarily driven by clinical factors and patient preferences, cost of treatment can be an important consideration if multiple options are considered equally appropriate. The formulas presented provide a simple, objective means of quickly comparing direct product costs for treating an HAE attack using local pricing figures.
Introduction
n Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening chronic disease associated with frequent, unpredictable attacks of painful, non-pitting, non-pruritic edema. 1, 2 n Since 2009, four highly effective agents have received FDA approval for the on-demand treatment of acute attacks of HAE: pasteurized, nanofiltered, plasma-derived C1-INH concentrate (pnfC1-INH/Berinert ® ), ecallantide (Kalbitor ® ), icatibant (Firazyr ® ); and recombinant human C1-INH (rhC1-INH/Ruconest ® ) ( Table 1) . Another plasma-derived C1-INH concentrate (Cinryze ® ) is approved for prophylaxis only and is not included.
n Drug treatments designed for orphan diseases such as HAE can be particularly expensive. 3, 4 While cost should only be one of many factors considered in choosing appropriate therapy, the economic realities of today's healthcare environment warrant such considerations, particularly when multiple therapies are deemed clinically viable options.
n Comparing HAE treatments on a relevant basis of cost-per-treated-attack is complicated because of differences in product dosing strategies (body weight-based versus fixed dosing) and potential likelihood for re-dosing to control a given attack.
n We designed cost estimation formulas that factor in these different variables and provide a quick and simple tool for roughly estimating comparative costs for the various HAE products; the objective was to design formulas that incorporate the user's own unique product acquisition costs, realizing that purchasing plans and cost structures are often institutionspecific and manufacturer pricing changes over time.
Methods
n Simple cost estimation formulas that factor in the non-static variables of body weight and re-dosing likelihood per attack were developed based on official prescribing recommendations and published clinical study data; costs of injection/infusion equipment were not included and would be expected to contribute little difference between the products.
n The two major determinants of HAE treatment costs per product considered in the formulas are 1) patient body weight and 2) re-dosing potential per attack.
1. Patient body weight -The cost estimation formulas were designed to encompass three theoretical patient weight categories: < 40 kg (to reflect small adults or pediatric patients), a standard 75 kg adult, and obese patients weighing between 100-125 kg.
• Dosing recommendations are body weight-based for pnfC1-INH.
• Dosing recommendations are fixed for icatibant and ecallantide
• Dosing recommendations for rhC1-INH are body weight-based for patients < 84 kg and fixed dose for patients < 84 kg (Table 1) .
2. Re-dosing potential -The formulas were weighted according to the potential need for re-dosing for a given attack, based upon re-dosing/rescue treatment rates reported in published clinical trials (Table 2 ).
• If more than one re-dosing rate appeared in published studies, the most favorable reported rate for each product was used as a conservative approach.
Cost Estimation Formulas
n The first step in estimating cost per attack is determining the quantity of units (vials or syringes) required to treat a single attack, per FDA product labeling.
-Icatibant and ecallantide are approved to be administered as a single 30 mg dose, while pnfC1-INH and rhC1-INH are dosed based on patient weight (Table 3) .
n The additional cost to account for potential re-dosing is determined by multiplying the acquisition cost of the initial dose by a factor that conservatively reflects percentage of attacks that may require re-dosing; this extra cost is added to the cost of the initial dose. The formula is shown here in simplified form:
Attack treatment cost = AC + (AC X RD%) Where AC = acquisition cost/dose; RD = re-dosing n Table 3 provides specific formulas for each of the HAE products, including a breakdown by body weight categories for those products that are dosed according to weight.
n The following hypothetical example illustrates use of the formula to estimate the treatment cost of a product having an acquisition cost of $3000 per unit (eg, syringe or vial), 1 unit required per dose, and a retreatment factor of 5%: -Attack treatment cost = $3000 + ($3000 X .05) = $3150
n The user's individualized acquisition costs for product vials and syringes are inserted into the formulas in Table 3 (italicized text).
Conclusions
n Cost should never be the sole driver of treatment decisions, but is often a factor to be considered among other clinical and situational determinants of management choices in patients with HAE.
n In the current economic environment, it is important that clinicians and payers have an appreciation for cost differentials if multiple treatment strategies are under consideration and otherwise considered viable clinical options.
n One limitation of developing these formulas was sourcing re-dosing rates from studies with design and terminology differences.
n The formulas presented here are simple and transparent for implementation using local prices and allow for a rough comparison of on-demand treatment product costs for a single HAE attack, factoring in the clinical reality of potential re-dosing, which adds to the cost of treating an attack. a N treated with study medication at approved dosage b Reported as re-dosing with study drug or administration of rescue medication in studies allowing only a single dose of study medication c 95% confidence interval NA = not assessed or not available; TXA = oral tranexamic acid Bold = lowest reported rate; used in formulas Table 3 . Per-attack cost estimation formulas for HAE products, factoring in patient weight and re-dosing potential. Formulas allow insertion of institutional/facility-specific acquisition costs per vial or syringe (italicized text). a Estimated need for re-dosing in a single attack: factors were 1% for pnfC1-INH, 9% for icatibant, 12% for ecallantide, and 9% for rhC1-INH, based on lowest percentage available in published studies (see Table 1 ) b Vial quantities rounded up to nearest whole vial pnfC1-INH = pasteurized, nanofiltered C1-INH; rhC1-INH = human recombinant C1-INH
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